HPV vaccine trends point to failures in patient education, vaccine programs
Completion rates for the human papillomavirus (HPV) vaccine series across both genders continue to remain alarmingly low nearly seven years after its introduction, suggesting that better patient education and increased public vaccine financing programs are needed, according to new research from the University of Texas Medical Branch (UTMB).
The researchers report "startling" trends in a series of three separate studies published in Cancer, Human Vaccines & Immunotherapeutics and Vaccine.
Using data from the 2010 National Health Interview Survey, an annual cross-sectional survey tracking more than 27,000 adults in the US., researchers found:
- More than three-quarters of nearly 2,000 women ages 18-26 did not receive the HPV vaccine; another 10% were incompletely vaccinated (three doses required); and two-thirds said they did not want the vaccine, an attitude the researchers attribute to inadequate knowledge, lack of physician recommendation or negative beliefs about vaccines.
- Just two percent of nearly 3,000 males ages 9-17 initiated the vaccine and fewer than half of those (0.5%) completed the three-dose series during 2010, the first full year when the vaccine was formally recommended for boys.
Analyzing private insurance claims from 2006-2009:
- Of 514 privately insured males ages 9-26 who initiated the HPV vaccine series, only 21% completed the series on an off-label basis within the recommended 12 months, and rates decreased over the period – a surprising result, the researchers said, as they surmised that the patient and/or their parents were motivated to obtain the vaccine before the FDA approved it for male use.
While cost was a barrier for completion, lack of awareness and understanding about the vaccine continue to be the biggest hindrances. These obstacles were especially pertinent for low-income and/or uninsured families and minority women. The researchers recommend better educational interventions; new physician-patient communication methods, including email and text message; increased physician recommendations; and public vaccine financing programs to increase uptake and completion rates across the board.
This latest research provides a broader picture of HPV vaccine acceptance and builds on a growing body of knowledge at UTMB in this area. Previous studies led by Berenson have focused on completion rates among females ages 9-27 and differences in parents' willingness to vaccinate their sons and daughters.
An estimated 20 million Americans ages 15-49 are currently infected with HPV, and at least 50% of sexually active men and women will contract it at some point in their lives. The virus is the cause of nearly all cases of cervical cancer and nearly 90% of genital warts. HPV is also associated with vulvar, vaginal, penile, anal, and oropharyngeal cancers.
"These results underscore the critical need for better educational interventions and improved communication methods – for patients, parents and physicians – about the importance of initiating and completing the HPV vaccine to save our children from serious disease," said Berenson. "It is especially important to reach parents, who need to understand that this vaccine will help them do what all parents want most – protect their children from harm."
Journal reference: Vaccine
Provided by University of Texas Medical Branch at Galveston
- HPV vaccine completion rate among girls is poor, getting worse May 05, 2012 | not rated yet | 0
- One in four California adolescent girls has had HPV vaccine Feb 17, 2009 | not rated yet | 0
- Study: Males should be given HPV vaccine Nov 28, 2007 | not rated yet | 0
- HPV vaccine reduces infection, even in unvaccinated Jul 09, 2012 | not rated yet | 0
- US recommends routine HPV vaccination for boys Feb 03, 2012 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
Medications 3 hours ago | not rated yet | 0
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications May 23, 2013 | 1 / 5 (1) | 0
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications May 23, 2013 | 5 / 5 (1) | 0
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications May 22, 2013 | not rated yet | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
3 hours ago | not rated yet | 4
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
3 hours ago | not rated yet | 1
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
22 hours ago | 3.7 / 5 (3) | 3 |
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
19 hours ago | 3 / 5 (2) | 0 |
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
3 hours ago | not rated yet | 0
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
22 hours ago | 5 / 5 (5) | 0 |